Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05841615
Other study ID # 2022-RDN and PVI
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2023
Est. completion date April 30, 2028

Study information

Verified date March 2024
Source The First Affiliated Hospital of Xiamen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The close relationship between the increase of sympathetic tension, AF, and HTN cannot be ignored. In addition, the significant failure rate of PVI (20-50%) in the treatment of AF makes it very necessary to explore the effect of RDN on AF. Therefore, this study aims to compare the effects and safety of PVI alone and PVI combined with RDN with AF combined with HTN, which will open a new chapter for PVI combined with RDN in the treatment of AF.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date April 30, 2028
Est. primary completion date April 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - 18<age<75years - clinic blood pressure=140/90mmHg or 24-hour ambulatory blood pressure monitoring average blood pressure =135/85mmHg - Ecg diagnosis of atrial fibrillation ; - who signed informed consent and were approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University. Exclusion Criteria: - pregnant women or lactating patients; - Patients who were unsuitable for ablation before surgery (unilateral or bilateral renal artery shape and structure were found: renal artery stenosis exceeding 50%, renal aneurysm, previous renal artery interventional surgery, renal artery malformation, renal artery diameter < 4mm or length of treatable segment < 20mm) - Patients who only have one kidney or have a history of kidney transplantation - Patients with a history of renal arterial intervention or renal denervation - identified secondary hypertension or Pseudo hypertension except for renal parenchymal hypertension; - malignant tumors or end-stage diseases; - Severe peripheral vascular disease, abdominal aortic aneurysm - whose left atrium is larger than 55mm - obvious bleeding tendency and blood system diseases; - Severe peripheral vascular disease, abdominal aortic aneurysm; - A history of the acute coronary syndrome within two weeks; - acute or severe systemic infection; - drug or alcohol dependence or refusal to sign informed consent. - Other conditions that are not suitable for PVI and RDN

Study Design


Intervention

Other:
Renal Denervation operation
RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W~12W for 40 seconds
Pulmonary vein isolation
PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.

Locations

Country Name City State
China the first affiliated hopital of Xiamen University Xiamen Fujian

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital of Xiamen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Malignant end point event 1 Fatal and nonfatal stroke within 2 years post operation
Primary Malignant end point event 2 cerebral hemorrhage within 2 years post operation
Primary Malignant end point event 3 acute myocardial infarction within 2 years post operation
Primary Malignant end point event 4 cardiovascular death within 2 years post operation
Secondary Complex end point event 1 Hospitalization for heart failure within 2 years post operation
Secondary Complex end point event 2 elevation of blood pressure(mmHg, upper arm blood pressure electronic monitor) within 2 years post operation
Secondary Complex end point event 3 left ventricular hypertrophy(mm, by Cardiac color ultrasound) within 2 years post operation
Secondary Complex end point event 4 coronary revascularization(by coronary arteriography) within 2 years post operation
Secondary Complex end point event 5 transient ischemic attack within 2 years post operation
Secondary Complex end point event 6 renal insufficiency (eGFR ml/min, by ECT); within 2 years post operation
Secondary Complex end point event 7 renal artery stenosis(by renal arteriography) within 2 years post operation
Secondary Complex end point event 8 proteinuria(mg/L, PRM assay) within 2 years post operation
Secondary Complex end point event 9 the recurrence rate of atrial fibrillation within 2 years post operation
Secondary Complex end point event 10 the control rate of blood pressure within 2 years post operation
See also
  Status Clinical Trial Phase
Recruiting NCT03750435 - Non-fluoroscopy Ablation of AF/AT N/A
Completed NCT04193813 - Predictors of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Prospective Cohort Study
Recruiting NCT04577859 - Oesophageal Protection Study: A Multicentre Study. N/A
Not yet recruiting NCT05168189 - the Role of Ivabradine in Causing AF in Patients With Chronic Coronary Syndrome